VIA
ENVB icon

Vident Investment Advisory’s Enveric Biosciences ENVB Stock Holding History

Vident Investment Advisory’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3
Closed -$24K – 1288
2021
Q4 		$24K Hold
3
– – ﹤0.01% 1200
2021
Q3 		$52K Buy
+3
New +$58.2K ﹤0.01% 1144

Other funds holding ENVB

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vident Investment Advisory's ENVB Position: Q1 2022 in Review

Vident Investment Advisory sold out of Enveric Biosciences (ENVB) in Q1 2022, closing a stake of 3 shares — an estimated $24K sold.

Vident Investment Advisory first reported a position in ENVB in Q3 2021 and held it in 2 quarters. The position peaked at $52K in Q3 2021. 26 funds tracked by Wall St. Rank hold ENVB as of Q1 2022.

  • Vident Investment Advisory reported no remaining Enveric Biosciences position as of Q1 2022 after selling out during the quarter.
  • Vident Investment Advisory sold 3 Enveric Biosciences shares in Q1 2022, an estimated $24K.
  • Vident Investment Advisory first reported a position in Enveric Biosciences in Q3 2021 and held it in 2 quarters.
  • Vident Investment Advisory's Enveric Biosciences position peaked at $52K in Q3 2021.
  • 26 funds tracked by Wall St. Rank held Enveric Biosciences as of Q1 2022.

Based on Vident Investment Advisory's 13F filing for Q1 2022, filed 16 May 2022.